Sahajanand Medical IPO
Sahajanand Medical IPO Listing Day Performance
Sahajanand Medical listed on BSE & NSE on 23 October 2026 at ₹371.15, a 7.89% premium over the issue price of ₹344. A retail investor allotted one lot of 43 shares gained ₹1,167 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹17 (+4.9%) |
| GMP-implied listing | ₹361 |
| Actual listing | ₹371.15 |
| Difference | +₹10.15 (+2.8%) |
Demand going into listing
| Subscribed overall | 14.2× |
| QIB | 34.7× |
| NII | 14.64× |
| Retail | 3.03× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Final |
|---|---|---|---|
| QIB | 0.37x | 1.12x | 34.70x |
| NII | 0.20x | 0.51x | 14.64x |
| bNII > ₹10L | 0.13x | 0.38x | 16.37x |
| sNII 2-10L | 0.36x | 0.77x | 11.19x |
| Retail | 0.40x | 0.83x | 3.03x |
| Employee | 0.08x | 0.14x | 0.37x |
| Total | 0.34x | 0.82x | 14.20x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2024 | 2025 | 2026 | June 2026 |
|---|---|---|---|---|
| Revenue | 908.59 | 1,035.96 | 1,218.73 | 354.33 |
| Expense | 875.50 | 980.12 | 1,138.43 | 330.05 |
| Profit (PAT) | 7.35 | 25.15 | 69.08 | 15.09 |
| Total Assets | 970.58 | 1,094.90 | 1,276.43 | 1,308.10 |
Peer Comparison
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Sahajanand Medical This IPO | 6.67 | - | 10.60 | 62.76 | - |
| Poly Medicure Limited | 31.79 | 51.40 | 10.37 | 306.40 | 1,875.26 Cr |
| Laxmi Dental Limited | 5.27 | 36.35 | 11.91 | 44.27 | 277.86 Cr |
Strengths & Risks
- Heavily oversubscribed — 14.2x overall (final).
- Strong institutional (QIB) demand — 34.7x.
- Revenue grew 18% in the latest reported year.
Our data checks haven't flagged a specific concern for Sahajanand Medical — but that isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.
From this issue's live data. Not investment advice — read the RHP.
Sahajanand Medical IPO: Lead Manager & Registrar Track Record
Lead manager: Motilal Oswal Investment Advisors Ltd.
Apart from Sahajanand Medical, Motilal Oswal Investment Advisors Ltd. has managed 19 IPOs we track (19 Mainboard, 0 SME). Of the 19 that have listed, 16 opened at or above the issue price (84%), with an average listing-day move of +11.3% and a median of +6.7%. The average across all 114 Mainboard listings we track is +13.6%.
Best listing: CMR Green Technologies +43.4% · Weakest: Waterways Leisure Tourism −15.7%
| IPO | Listed | Listing-day move |
|---|---|---|
| EAAA India Alternatives | 02 Nov 2026 | +0.6% |
| Fusion CX | 22 Oct 2026 | +5.5% |
| NSE | 24 Sept 2026 | +0.8% |
| Manipal Payment | 17 Sept 2026 | −2.1% |
| LCC Projects | 17 Sept 2026 | +31.4% |
Lead manager: Avendus Capital Pvt.Ltd.
Apart from Sahajanand Medical, Avendus Capital Pvt.Ltd. has managed 6 IPOs we track (6 Mainboard, 0 SME). Of the 6 that have listed, 5 opened at or above the issue price (83%), with an average listing-day move of +2% and a median of +2.6%. The average across all 114 Mainboard listings we track is +13.6%.
Best listing: SEDEMAC Mechatronics +13.5% · Weakest: Amagi Media Labs −12.2%
| IPO | Listed | Listing-day move |
|---|---|---|
| Zetwerk | 23 Oct 2026 | +5.5% |
| NSE | 24 Sept 2026 | +0.8% |
| Symbiotec Pharmalab | 01 Sept 2026 | +0% |
| LEAP India | 14 Aug 2026 | +4.3% |
| SEDEMAC Mechatronics | 11 Mar 2026 | +13.5% |
Lead manager: HSBC Securities & Capital Markets (India) Pvt.Ltd.
Apart from Sahajanand Medical, HSBC Securities & Capital Markets (India) Pvt.Ltd. has managed 7 IPOs we track (7 Mainboard, 0 SME). Of the 7 that have listed, 6 opened at or above the issue price (86%), with an average listing-day move of +6.7% and a median of +6.7%. The average across all 114 Mainboard listings we track is +13.6%.
Best listing: Jio Platforms +21.4% · Weakest: Clean Max Enviro −8.8%
| IPO | Listed | Listing-day move |
|---|---|---|
| Jio Platforms | 28 Oct 2026 | +21.4% |
| Zetwerk | 23 Oct 2026 | +5.5% |
| Juniper Green Energy | 06 Aug 2026 | +8.9% |
| Cube Highways Trust InvIT | 31 Jul 2026 | +2% |
| SBI Funds Management | 21 Jul 2026 | +6.7% |
Lead manager: Nuvama Wealth Management Ltd.
Apart from Sahajanand Medical, Nuvama Wealth Management Ltd. has managed 12 IPOs we track (12 Mainboard, 0 SME). Of the 11 that have listed, 9 opened at or above the issue price (82%), with an average listing-day move of +4.4% and a median of +3.9%. The average across all 114 Mainboard listings we track is +13.6%.
Best listing: Augmont Enterprises +22% · Weakest: Powerica −7.3%
| IPO | Listed | Listing-day move |
|---|---|---|
| SFC Environmental | 03 Nov 2026 | +7.6% |
| EAAA India Alternatives | 02 Nov 2026 | +0.6% |
| Paras Healthcare | 28 Oct 2026 | +3.9% |
| Fusion CX | 22 Oct 2026 | +5.5% |
| NSE | 24 Sept 2026 | +0.8% |
Registrar: MUFG Intime India Pvt. Ltd.
MUFG Intime India Pvt. Ltd. is the registrar for 65 other IPOs we track (43 Mainboard, 22 SME). It finalises the basis of allotment, credits shares and processes refunds for Sahajanand Medical; 46 of the 62 it handled that have listed opened at or above the issue price.
How Sahajanand Medical compares with recent Mainboard IPOs
- Subscribed 14.2x overall, against a median of 20.56x for the 111 Mainboard IPOs listed in the last 12 months — higher than 46% of them.
- Listed at +7.9% on day one, against a median of +6.7% for 113 Mainboard listings in the last 12 months — better than 55% of them.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Past listings don't predict this one.
Company Information
Sahajanand Medical at a glance
From the company's description: “Incorporated in 2001, Sahajanand Medical Technologies is a medical device firm that focuses on Class III and Class C/D devices, mainly working in the fields of vascular and structural heart intervention.”
Sahajanand Medical is raising ₹476 crore through an IPO on the BSE and NSE mainboard.
Revenue went from ₹909 crore in 2024 to ₹1,219 crore in 2026, up 34% over 2 years. Profit after tax went from ₹7.35 crore to ₹69.08 crore, a net margin of 5.7% in the latest year.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Sahajanand Medical Technologies Ltd., Sahajanand Estate, Wakharia Wadi,, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat, 395004
Resources & Documents
Sahajanand Medical IPO - Quick Take
Sahajanand Medical has set a price band of Rs 327–Rs 344 per share for an issue size of Rs 476 crore. The stock listed with a 7.89% gain versus its issue price on October 23, 2026.
The issue is promoted by Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust with Motilal Oswal Investment Advisors Ltd., Avendus Capital Pvt.Ltd., HSBC Securities & Capital Markets (India) Pvt.Ltd., Nuvama Wealth Management Ltd. acting as lead manager.
On fundamentals, the company is posting revenue growth of 17.6%, a profit margin of 5.7% in its most recent reported period. Listed peers in this segment include Poly Medicure Limited (P/E 51.40x) and Laxmi Dental Limited (P/E 36.35x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Frequently Asked Questions
Sahajanand Medical IPO GMP — What It Means
Its last GMP before listing was 4.9%. Of the 40 Mainboard IPOs we have tracked with a final GMP under 10%, 27 listed above, 6 flat and 7 below the issue price; Sahajanand Medical listed 7.9% above its issue price.
See the full Sahajanand Medical GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Sahajanand MedicalNo comments yet. Be the first to share your opinion!